Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone, also known as 3,4-Dihydro-7-Hydroxy-2(1H)-Quinolinone, (CAS: 22246-18-0) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Chemical Name |
7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone |
Synonyms |
3,4-Dihydro-7-Hydroxy-2(1H)-Quinolinone; 7-Hydroxy-3,4-Dihydrocarbostyril; 7-Hydroxy-2-oxo-1,2,3,4-Tetrahydroquinoline; 7-Hydroxycarbostyril; Aripiprazole Impurity 5; Aripiprazole EP Impurity A |
CAS Number |
22246-18-0 |
CAT Number |
RF-PI1981 |
Stock Status |
In Stock, Production Capacity 60MT/Year |
Molecular Formula |
C9H9NO2 |
Molecular Weight |
163.18 |
Solubility |
Soluble in Methanol |
Density |
1.282±0.060 g/cm3 |
Brand |
Ruifu Chemical |
Item |
Specifications |
Appearance |
Pale Yellow or Almost White Powder |
Purity / Analysis Method |
>99.5% (HPLC, Area Percentage) |
Melting Point |
229.0~235.0℃ |
Loss on Drying |
<0.50% |
Water Content (K.F) |
<0.50% |
Maximum Single Impurity |
<0.30% |
Total Impurities |
<0.50% |
Infrared Spectrum |
Conforms to Structure |
Test Standard |
Enterprise Standard |
Usage |
Intermediate of Aripiprazole (CAS: 129722-12-9)
|
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Methyl 3-Bromobenzoate (CAS 618-89-3) can be used as the precursor of Aripiprazole (CAS: 129722-12-9). Aripiprazole is a new kind of highly lipid soluble quinoline derivatives, its pharmacological effects characteristic is that it is not only the postsynaptic dopamine D 2 receptor antagonist, but also the presynaptic dopamine D 2 receptor agonist,it can also excite D 1, D 3, D 4 receptors; Aripiprazole has dual effect of partial activation or receptor antagonistic on 5-HT 1A receptor; it has a completely antagonistic action on the 5-HT 2A receptor. This feature is different from the first generation, and atypical antipsychotics which belong to the second-generation antipsychotic drugs, and therefore it is called dopamine system stabilizer or third generation antipsychotic. Since it is sold in the market, Aripiprazole is mainly used in clinical schizophrenia, treatment of affective disorders and other psychiatric disorders. According to the literature, aripiprazole has significant effects on schizophrenia positive and negative symptoms and anxiety, depression, cognitive function, while higher safety. Aripiprazole was also reported that the drug can also treat other mental disorders, such as mood disorders manic episodes, senile dementia associated with mental disorders, anxiety disorders, children's behavioral disorders, depression.